Media
News
Financial Times
Financial Times: Swiss group says its machines can conduct 30m virus antibody tests this year

Quotient warns global shortages of critical components could hamper efforts

To read the full article, visit: Financial Times

Read More
SARS-CoV-2 Microarray
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development

JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1

Read More
Lab
Quotient Limited to Host Investor Information Conference Call and Live Webcast

Link to webcast

 

Read More
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

JERSEY, Channel Islands, Feb.

Read More
Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call
Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.

Read More
Quotient aims to reduce the time to receive blood test results
Quotient aims to reduce blood testing time

C’est une revolution dans l’univers de l’analyse de sang. Quotient, une société basée à Eysins (VD), aux portes de Nyon, met sur le marché une nouvelle technique qui permet d’obtenir des résultats complets d’un échantillon avec une grande rapidité.

Read More
Image
Quotient at AABB 2019

Quotient is attending the 2019 AABB Annual Meeting in San Antonio, TX, from 19-22 October 2019.

Read More